Trial Profile
An Open-Label Study to Evaluate the Safety of Long-Term Administration of Product 33525 in Subjects With Tinea Pedis, Tinea Corporis, or Tinea Cruris
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Apr 2014
Price :
$35
*
At a glance
- Drugs Luliconazole (Primary)
- Indications Tinea corporis; Tinea cruris; Tinea pedis
- Focus Adverse reactions
- Sponsors Tinea Pharmaceuticals Inc
- 21 Apr 2014 New trial record